Servier CDMO, the contract development and manufacturing organization (CDMO) division of Servier, today announced that the company has invested $7.5 million in intensified technology including continuous chromatography with simulated moving bed (SMB) and super critical fluid chromatography (SFC) with solvent recycling of up to 90 percent to lower environmental impact.
Servier CDMO expects at least a 50 percent increase in productivity in addition to the existing configuration of the high-volume batch columns that are used to manufacture drug substances. The investment will allow the chemical purification of 50kg (kilograms) per day, and the chiral separation of 10kg per day to support clinical trials and market supply upon drug approvals.
The highly qualified team at the Bolbec site, in Normandy, is composed of experts in chemical processes and is certified to handle highly potent compounds to occupational exposure band five (OEB 5). Bolbec is a fully United States Food & Drug Administration (FDA) current good manufacturing practice (cGMP) site for human pharmaceuticals.
Servier CDMO believes that this exceptional expertise and technology give pharmaceutical companies access to the means to accelerate the development and commercialization of novel therapies that will meet significant unmet patient needs for highly potent compounds.
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). It has an international presence in 148 countries.
(Source: Servier CDMO)